PMID- 28151455
OWN - NLM
STAT- MEDLINE
DCOM- 20170302
LR  - 20181113
IS  - 0975-4466 (Electronic)
IS  - 0256-4947 (Print)
IS  - 0256-4947 (Linking)
VI  - 37
IP  - 1
DP  - 2017 Jan-Feb
TI  - Association of human leukocyte antigen DRB1 with anti-cyclic citrullinated 
      peptide autoantibodies in Saudi patients with rheumatoid arthritis.
PG  - 38-41
LID - 10.5144/0256-4947.2017.38 [doi]
AB  - BACKGROUND: The genetic association between human leukocyte antigen (HLA)-DRB1 
      alleles and the risk of development of autoantibodies has been investigated, but 
      there are few studies from the Gulf region. OBJECTIVES: To investigate the 
      association between the HLA-DRB1 shared epitope and the risk for development of 
      autoantibodies in rheumatoid arthritis (RA) patients in a Saudi population. 
      DESIGN: Analytical cross-sectional study. SETTING: Tertiary care hospital in 
      Riyadh, Saudi Arabia. PATIENTS AND METHODS: We enrolled consecutive Saudi RA 
      patients attending the rheumatology clinic between January and April 2015. 
      Previously published data on HLA typing on unmatched healthy controls were used 
      for comparison. HLA typing was performed using sequence-specific oligonucleotide 
      probes (SSOP). Rheumatoid factor (RF), anti-cyclic citrullinated peptide 
      (anti-CCP) antibodies, and antinuclear antibodies (ANA) were also measured. 
      Logistic regression analysis was used to study the autoantibodies as possible 
      explanatory variables for the presence of the HLA-DRB1 shared epitope. MAIN 
      OUTCOME MEASURE(S): The association between the presence of the shared epitope 
      and the risk of developing anti-CCP antibodies, ANA, and RF. RESULTS: In 76 
      patients with RA, carrying the shared epitope was associated with a significantly 
      higher risk of having RA [OR=2.65, 95% CI (1.42-4.94), P=.0009]. However, only 
      HLA-DRB1*04:05 was significantly as.sociated with RA [OR=3.73, 95% CI 
      (1.61-8.96), Pc=.016]. In the logistic regression analysis, only anti-CCP was 
      significantly associated with the shared epitope [OR=14.51, 95% CI (1.53-137.49), 
      P=.02]. CONCLUSIONS: Our analysis indicates that the presence of the HLA-DRB1 
      shared epitope is strongly associated with the development of anti-CCP antibodies 
      in Saudi patients with RA. LIMITATIONS: A larger sample size is needed to confirm 
      our finding.
FAU - Alrogy, Abdullah
AU  - Alrogy A
FAU - Dirar, Abduallah
AU  - Dirar A
FAU - Alrogy, Waleed
AU  - Alrogy W
FAU - Fakhoury, Hana
AU  - Fakhoury H
FAU - Hajeer, Ali
AU  - Hajeer A
AD  - Prof. Ali Hajeer, King Saud bin Abdulaziz University for Health Sciences,, 
      Immunology, National Guard Health Affairs,, Riyadh, 11426, Saudi Arabia, T: 
      966-11-4294047, F: 966-11-2520130, hajeera@ksau-hs.edu.sa, ORCID: 
      orcid.org/0000-0003-2727-9964.
LA  - eng
PT  - Journal Article
PL  - Saudi Arabia
TA  - Ann Saudi Med
JT  - Annals of Saudi medicine
JID - 8507355
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Autoantibodies)
RN  - 0 (Epitopes)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Peptides, Cyclic)
RN  - 0 (cyclic citrullinated peptide)
RN  - 9009-79-4 (Rheumatoid Factor)
SB  - IM
CIN - Ann Saudi Med. 2017 Jul-Aug;37(4):338. PMID: 28761036
CIN - Ann Saudi Med. 2017 Jul-Aug;37(4):338-339. PMID: 28761037
MH  - Adult
MH  - Age of Onset
MH  - Antibodies, Antinuclear/blood
MH  - Arthritis, Rheumatoid/*blood
MH  - Autoantibodies/*blood
MH  - Case-Control Studies
MH  - Cross-Sectional Studies
MH  - Epitopes
MH  - Female
MH  - HLA-DRB1 Chains/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptides, Cyclic/*blood/immunology
MH  - Rheumatoid Factor/blood
MH  - Saudi Arabia
MH  - Sex Factors
PMC - PMC6148974
EDAT- 2017/02/06 06:00
MHDA- 2017/03/03 06:00
PMCR- 2017/01/01
CRDT- 2017/02/03 06:00
PHST- 2017/02/03 06:00 [entrez]
PHST- 2017/02/06 06:00 [pubmed]
PHST- 2017/03/03 06:00 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - asm-37-1-38 [pii]
AID - 10.5144/0256-4947.2017.38 [doi]
PST - ppublish
SO  - Ann Saudi Med. 2017 Jan-Feb;37(1):38-41. doi: 10.5144/0256-4947.2017.38.